Please login to the form below

Not currently logged in


This page shows the latest imlygic news and features for those working in and with pharma, biotech and healthcare.

J&J pays $140m upfront for cancer-busting virus firm BeneVir

J&J pays $140m upfront for cancer-busting virus firm BeneVir

Amgen’s Imlygic (talimogene laherparepvec) has been approved in Europe and the US since 2015 for use in melanoma that has recurred after surgery, but sales have been small.

Latest news

More from news
Approximately 5 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...